U.S., May 31 -- ClinicalTrials.gov registry received information related to the study (NCT06997627) titled 'A Phase I/II Study to Evaluate the Safety and Immunogenicity of GC3111B in Healthy Adults' on May 15.
Brief Summary: This clinical trial consists of two parts: Part 1, which explores safety, and Part 2, which examines both safety and efficacy (immunogenicity). Part 1 is a single-center, open-label, single-group study, while Part 2 is designed as a multicenter, double-blind, randomized, active-controlled trial.
Study Start Date: June, 2025
Study Type: INTERVENTIONAL
Condition:
Tetanus-diphtheria-acellular Pertussis (Tdap)
Intervention:
BIOLOGICAL: GC3111B
0.5 mL, Intramuscular injection
BIOLOGICAL: Boostrix(R)
0.5 mL, Intramu...